• June 3-6, 2024
  • San Diego Convention Center, California



Allife Medicine

Thursday, June 06, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 2
Founded in 2017, by scientists from China and the UK, Allife Medicine has been at the forefront of advancing healthcare, through universal, off-the-shelf, and innovative cell medicine and gene therapy. Operating globally in China, the UK, and Malaysia, we take pride in pioneering China's, first iPSC derived cell therapy clinical trial, marking a historic milestone in the field. Our team, comprising nearly two hundred experts, forty-five of whom hold PhD degrees, has been instrumental in, generating over one hundred patents, and publishing more than eighty research papers, in international peer-reviewed journals. Our product pipelines showcase Phase one products: ALF201 and ALF202 targeting Acute Ischemic Stroke and Peripheral Limb Ischemia. It has demonstrated a significant improvement in stroke prognosis, extending the treatment window and providing hope to, the 70% of patients who are ineligible for intravenous thrombolytic therapy.
Allife Medicine
Company Website: http://www.allifetech.com
Lead Product in Development: 1. iEPC for Acute Ischemic Stroke and Peripheral Limb Ischemia 2. EPC Gene Therapy for Erectile Dysfunction (ED) 3. CAR NK for tumor treatment
Number Of Unlicensed Products (For Which You Are Seeking Partners): Forty-eight patents ready for licensing.

Company HQ City


Company HQ State


Company HQ Country


CEO/Top Company Official

CEO - Yuchun Gu CTO - Shengjiang Tan Vice President Lily Jiang Vice President Xiaoqing Liu

Development Phase of Primary Product

Phase I
Primary Speaker
Zemin Ning
Dr Zemin Ning
ALLIFE Medicine
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.